Hepatosplenic T-cell Lymphoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2023-02-21
Clinical Trial Update: CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) [Phase 2, Phase 3]
Clinical trial CELTIC-1 evaluating cerdulatinib in relapsed/refractory peripheral T-cell lymphoma has been withdrawn from the study.